ArticleFrontiers in oncology2025
Allergic history and responses to immunotherapy in individuals with recurrent or metastatic head and neck squamous cell carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To elucidate the association between allergy history and response to immune checkpoint inhibition (ICI) in recurrent or metastatic head and neck squamous cell carcinoma (RM/HNSCC). Methods: Patients receiving ICI treatment for RM/HNSCC were retrospectively enrolled and classified into two groups based on their previous allergy history. The primary outcome variable assessed was the response to ICI. Results: A total of 157 patients were included, of whom 27 reported a history of allergies. In multivariate analysis, patients with allergies exhibited an odds ratio of 2.78 [95% confidence interval: 1.54-5.99], significantly surpassing that of the non-allergic group. Other independent predictors of ICI benefit included current smoking status and the primary tumor site being in the oropharynx or hypopharynx. Neither progression-free survival nor overall survival was adversely affected by prior allergy history or smoking status or HPV status or PD-L1 expression. Conclusion: A prior history of allergies is associated with an enhanced response to immunotherapy in patients with RM/HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.